Published in Oncoimmunology on December 02, 2014
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology (2015) 0.86
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors. J Leuk (Los Angel) (2015) 0.76
Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. Biomolecules (2016) 0.75
Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 33.06
XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell (2001) 18.68
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev (1999) 13.24
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol (2003) 11.17
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med (1997) 8.59
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 8.27
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7.64
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell (2000) 5.56
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
ER stress and diseases. FEBS J (2007) 5.03
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity (2010) 4.52
Endoplasmic reticulum stress in liver disease. J Hepatol (2010) 3.90
Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity (2011) 3.58
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene (2006) 3.48
Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity (2005) 3.39
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A (2003) 3.23
Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (2001) 2.95
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood (2005) 2.95
The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene (2012) 2.82
Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res (2008) 2.81
Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol (2010) 2.63
Regulation of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat Med (2011) 2.40
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol (2003) 2.28
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol (2001) 2.15
The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol (2011) 2.10
Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J (2007) 1.82
Extensive pancreas regeneration following acinar-specific disruption of Xbp1 in mice. Gastroenterology (2011) 1.72
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol (2007) 1.64
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med (2012) 1.61
Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood (2003) 1.56
Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther (2006) 1.51
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol (2010) 1.38
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol (2010) 1.36
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res (2009) 1.34
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs (2010) 1.30
Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J Immunol (2011) 1.26
T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res (2011) 1.21
Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann N Y Acad Sci (2012) 1.21
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol (2010) 1.14
CMV-specific central memory T cells reside in bone marrow. Eur J Immunol (2007) 1.08
Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother (2012) 1.05
Growth inhibition of colon cancer cells by polyisoprenylated benzophenones is associated with induction of the endoplasmic reticulum response. Int J Cancer (2008) 1.03
The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut (2007) 1.03
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia (2011) 1.01
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res (2012) 0.96
canEvolve: a web portal for integrative oncogenomics. PLoS One (2013) 0.95
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs (2009) 0.92
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol (2013) 0.90
Preventing the unfolded protein response via aberrant activation of 4E-binding protein 1 by versipelostatin. Cancer Sci (2009) 0.89
Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. Int J Oncol (2010) 0.83
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Cancer Lett (2013) 0.83
A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother (2010) 0.82
Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation. Anticancer Res (2010) 0.80